BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Murai H, Suzuki S, Hasebe M, Fukamizu Y, Rodrigues E, Utsugisawa K. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance. Ther Adv Neurol Disord 2021;14:17562864211001995. [PMID: 33796147 DOI: 10.1177/17562864211001995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Waheed W, Newman E, Aboukhatwa M, Moin M, Tandan R. Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review. Ther Clin Risk Manag 2022;18:699-719. [PMID: 35855752 DOI: 10.2147/TCRM.S266031] [Reference Citation Analysis]
2 Dalakas MC. Role of complement, anti-complement therapeutics, and other targeted immunotherapies in myasthenia gravis. Expert Rev Clin Immunol 2022;:1-11. [PMID: 35730504 DOI: 10.1080/1744666X.2022.2082946] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Suh J, Clarke V, Amato AA, Guidon AC. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve 2022. [PMID: 35684980 DOI: 10.1002/mus.27656] [Reference Citation Analysis]
4 McCombe JA, Pittock SJ. Anti-complement Agents for Autoimmune Neurological Disease. Neurotherapeutics 2022. [PMID: 35553024 DOI: 10.1007/s13311-022-01223-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Jiao L, Li H, Guo S. Eculizumab treatment for myasthenia gravis subgroups: 2021 update. J Neuroimmunol 2022;362:577767. [PMID: 34823117 DOI: 10.1016/j.jneuroim.2021.577767] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Li J, Weng S, Lin S, Huang L, Yang X, Liang B, Lu J, Jiang Q. Evaluation of the Quantitative Myasthenia Gravis Score and Grip Strength in Chinese Patients With Myasthenia Gravis: An Observational Study. Front Neurol 2021;12:782980. [PMID: 35002931 DOI: 10.3389/fneur.2021.782980] [Reference Citation Analysis]
7 Xiao H, Wu K, Liang X, Li R, Lai KP. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis. Front Immunol 2021;12:715036. [PMID: 34456922 DOI: 10.3389/fimmu.2021.715036] [Reference Citation Analysis]
8 Schmidt C, Weißmüller S, Bohländer F, Germer M, König M, Staus A, Wartenberg-Demand A, Heinz CC, Schüttrumpf J. The Dual Role of a Polyvalent IgM/IgA-Enriched Immunoglobulin Preparation in Activating and Inhibiting the Complement System. Biomedicines 2021;9:817. [PMID: 34356880 DOI: 10.3390/biomedicines9070817] [Reference Citation Analysis]